An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
NCT04764188
·
clinicaltrials.gov ↗
ACTIVE_NOT_RECRUITING
Status
800
Enrollment
INDUSTRY
Sponsor class
Conditions
NSCLC
Interventions
DRUG:
Alectinib
Sponsor
Hoffmann-La Roche